To use magnesium sulphate for reducing fasciculations caused by etomidate during general anaesthesia.

To evaluate efficacy of magnesium sulphate in attenuating etomidate induced myoclonus.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/12/060470

Enrollment

100

Registered

2023-12-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: magnesium sulfate 30mg/kg diluted upto 10ml.: magnesium sulfate 30mg/kg diluted upto 10 ml administered 10 mins prior to etomidate administration Control Intervention1: normal saline 10

Eligibility

Inclusion criteria

Inclusion criteria: 1)Physical status ASA 1 and 2. 2)Patients scheduled for elective surgeries under general anaesthesia.

Exclusion criteria

Exclusion criteria: 1)Refusal for participation. 2)Any known allergy or contraindication to the drug used. 3)Cerebrovascular disease. 4)Intracranial hypertension. 5)ASA 3 and 4.

Design outcomes

Primary

Measure	Time frame
30 mg/kg of magnesium sulphate is expected to attenuate etomidate induced myoclonus.Timepoint: T0-pre-operative. T1-1st reading in operation theatre. T2-after magnesium sulphate(immediately). T3-after etomidate. T4-immediately after extubation.	—

Secondary

Measure	Time frame
incidence of hypotension,bradycardia,post-op nausea and vomiting.Timepoint: T0-pre-operative. T1-1st reading in operation theatre. T2-after magnesium sulphate(immediately). T3-after etomidate. T4-immediately after extubation.	—

Countries

India

Contacts

Public ContactAshlesha Bankar

Smt.Kashibai navale medical college and hospital,Narhe,Pune.

drnehaghule@gmail.com9689495891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026